Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

SAB Biotherapeutics, Inc. Director's Dealing 2021

Oct 23, 2021

34961_dirs_2021-10-22_8eecb8dd-e346-48b4-ad1b-5f2521874650.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Big Cypress Acquisition Corp. (SABS)
CIK: 0001833214
Period of Report: 2021-10-22

Reporting Person: Bausch Christoph Lawrence (Chief Science Officer)

More from SAB Biotherapeutics, Inc.

Interim / Quarterly Report 2026
May 12
Regulatory Filings 2026
May 4
Regulatory Filings 2026
Apr 22
Regulatory Filings 2026
Mar 31
Major Shareholding Notification 2026
Feb 17
Major Shareholding Notification 2026
Feb 17
Director's Dealing 2026
Feb 5
Director's Dealing 2026
Feb 5
Director's Dealing 2026
Feb 5
Director's Dealing 2026
Feb 5
View all filings →